Recent News
On August 5, 2025 Beam Therapeutics reported second-quarter 2025 results and clinical updates for BEAM‑302, noting 17 patients dosed in the Phase 1/2 program, durable correction of the disease‑causing mutation, and no dose‑limiting toxicities; the company indicated Parts A and B data and an updated development plan expected in early 2026. On August 25, 2025 the company announced management participation in multiple September 2025 investor conferences. Investor’s Business Daily reported a Relative Strength upgrade through late September 2025, noting the RS Rating moved above 80 and that the stock advanced beyond a cup‑with‑handle buy point.
Technical Analysis
ADX / DI+ / DI-: ADX at 46.45 indicates very strong trend strength; DI+ at 33.46 shows a dip‑and‑reverse (bullish) while DI‑ at 10.40 shows a peak‑and‑reverse (bullish). Together, directional indicators align with upward price bias and reinforce momentum-based valuation support.
MACD: MACD of 1.50 is above the signal line at 1.32 and trending higher, a bullish momentum confirmation that supports continued upside pressure relative to the current valuation.
MRO (Momentum/Regression Oscillator): MRO at 27.86 sits positive, indicating price currently sits above the model target and carries mean‑reversion risk; that condition raises the probability of a near‑term pullback from stretched levels.
RSI: RSI equals 58.68 and trends higher, showing constructive momentum without an overbought reading; momentum can persist while RSI remains below the 70 threshold.
Price vs Moving Averages & Ichimoku: Last close of $25.89 sits above the 12‑day EMA ($24.24), 20‑day average ($24.23), 50‑day average ($20.07) and 200‑day average ($21.50). Tenkan‑sen at 24.20 and Kijun‑sen at 21.25 provide intraday and intermediate support, reinforcing biased upside relative to WMDST’s valuation.
Bands, Support and Volumes: Close near the upper Bollinger band (upper 1× = $25.41; upper 2× = $26.60) suggests limited short‑run extension without consolidation. SuperTrend lower support sits at $23.19; volume currently matches recent 10‑day averages, indicating moves have average follow‑through.
Fundamental Analysis
Profitability & Earnings: Operating income (EBIT) equals -$120,151,000 and operating margin equals -14.19%. That margin sits below the industry peer mean of -0.73% and below the industry peer median of 0.24%, indicating margins remain weaker than peers even as operating margin improved year‑over‑year by 59.27% (operatingMarginYoY = 0.59274). EPS for the period printed -$1.00 versus an estimate of -$1.09, producing an EPS surprise of 8.26% (EPSsurpriseRatio = 0.08257).
Revenue & Cash Flow: Total revenue equals $8,466,000 and YoY revenue growth equals -77.35% (revenueGrowthYoY = -0.7735); operating cash flow totaled -$76,450,000 with free cash flow -$79,586,000. Cash and short‑term investments equal $1,150,337,000 and cash on hand equals $282,132,000, providing substantial liquidity against current operating deficits.
Balance Sheet & Leverage: Current ratio stands at 6.75 and cash ratio at 6.61, reflecting ample short‑term liquidity. Total debt equals $154,803,000, debt‑to‑assets equals 11.13%, and debt‑to‑equity equals 14.79%, indicating modest leverage relative to balance sheet size.
R&D and Investment Profile: Research and development expense of $101,758,000 represents a large absolute investment relative to revenue, consistent with an R&D‑intensive clinical‑stage biotech pursuing multiple programs across hematology and genetic disease franchises.
Valuation: Market capitalization equals $1,844,428,178 while enterprise value equals $848,894,178, reflecting a net cash position. WMDST values the stock as under‑valued, supported by a strong cash base that reduces enterprise exposure even as profitability lags and revenue contraction persists.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2025-06-30 |
| REPORT DATE: | 2025-08-05 |
| NEXT REPORT DATE: | 2025-11-04 |
| CASH FLOW | Begin Period Cash Flow | $ 534.5 M |
| Operating Cash Flow | $ -76.45 M | |
| Capital Expenditures | $ -3.14 M | |
| Change In Working Capital | $ 3.4 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ -245.75 M | |
| End Period Cash Flow | $ 288.8 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | $ 8.5 M | |
| Forward Revenue | $ 2.5 M | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | $ 5.5 M | |
| Depreciation and Amortization | $ 5.5 M | |
| Research and Development | $ 101.8 M | |
| Total Operating Expenses | $ 128.6 M | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | $ -114.61 M | |
| EBIT | $ -120.15 M | |
| Operating Income | $ -120.15 M | |
| Interest Income | $ 12.3 M | |
| Interest Expense | — | |
| Net Interest Income | $ 12.3 M | |
| Income Before Tax | $ -102.29 M | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | $ -102.29 M | |
| Net Income From Continuing Operations | $ -102.29 M | |
| EARNINGS | ||
| EPS Estimate | $ -1.09 | |
| EPS Actual | $ -1.00 | |
| EPS Difference | $ 0.09 | |
| EPS Surprise | 8.257 % | |
| Forward EPS | $ -1.19 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 1.4 B | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 1.0 B | |
| Total Current Assets | $ 1.2 B | |
| Cash and Short-Term Investments | $ 1.2 B | |
| Cash | $ 282.1 M | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | $ 7.3 M | |
| LIABILITIES | ||
| Accounts Payable | $ 10.6 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 174.1 M | |
| Net Debt | — | |
| Total Debt | $ 154.8 M | |
| Total Liabilities | $ 344.3 M | |
| EQUITY | ||
| Total Equity | $ 1.0 B | |
| Retained Earnings | $ -1.78 B | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 10.39 | |
| Shares Outstanding | 100.759 M | |
| Revenue Per-Share | $ 0.08 | |
| VALUATION | Market Capitalization | $ 1.8 B |
| Enterprise Value | $ 848.9 M | |
| Enterprise Multiple | -7.407 | |
| Enterprise Multiple QoQ | -24.803 % | |
| Enterprise Multiple YoY | -39.206 % | |
| Enterprise Multiple IPRWA | high: 47.216 median: 14.143 mean: 5.446 BEAM: -7.407 low: -68.907 |
|
| EV/R | 100.271 | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.329 | |
| Asset To Liability | 4.04 | |
| Debt To Capital | 0.129 | |
| Debt To Assets | 0.111 | |
| Debt To Assets QoQ | 3.228 % | |
| Debt To Assets YoY | 455.289 % | |
| Debt To Assets IPRWA | high: 0.995 mean: 0.187 BEAM: 0.111 median: 0.062 low: 0.0 |
|
| Debt To Equity | 0.148 | |
| Debt To Equity QoQ | 5.036 % | |
| Debt To Equity YoY | 399.595 % | |
| Debt To Equity IPRWA | high: 1.706 mean: 0.25 BEAM: 0.148 median: 0.059 low: -1.039 |
|
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 1.762 | |
| Price To Book QoQ | -9.32 % | |
| Price To Book YoY | -31.375 % | |
| Price To Book IPRWA | high: 16.592 median: 6.295 mean: 5.284 BEAM: 1.762 low: -10.064 |
|
| Price To Earnings (P/E) | -19.507 | |
| Price To Earnings QoQ | 11.458 % | |
| Price To Earnings YoY | -18.652 % | |
| Price To Earnings IPRWA | high: 46.94 mean: -9.521 median: -17.196 BEAM: -19.507 low: -73.374 |
|
| PE/G Ratio | 1.008 | |
| Price To Sales (P/S) | 217.863 | |
| Price To Sales QoQ | -25.425 % | |
| Price To Sales YoY | 16.954 % | |
| Price To Sales IPRWA | high: 517.227 BEAM: 217.863 mean: 55.943 median: 19.711 low: 0.25 |
|
| FORWARD MULTIPLES | ||
| Forward P/E | -15.546 | |
| Forward PE/G | 0.803 | |
| Forward P/S | 741.891 | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | 0.054 | |
| ASSET & SALES | ||
| Asset Turnover Ratio | 0.006 | |
| Asset Turnover Ratio QoQ | 1.893 % | |
| Asset Turnover Ratio YoY | -34.076 % | |
| Asset Turnover Ratio IPRWA | high: 0.388 mean: 0.115 median: 0.113 BEAM: 0.006 low: -0.001 |
|
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | — | |
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | 0.008 | |
| CapEx To Revenue | -0.37 | |
| CapEx To Depreciation | -0.566 | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.0 B | |
| Net Invested Capital | $ 1.0 B | |
| Invested Capital | $ 1.0 B | |
| Net Tangible Assets | $ 1.0 B | |
| Net Working Capital | $ 1.0 B | |
| LIQUIDITY | ||
| Cash Ratio | 6.606 | |
| Current Ratio | 6.75 | |
| Current Ratio QoQ | -23.414 % | |
| Current Ratio YoY | 16.285 % | |
| Current Ratio IPRWA | high: 25.128 BEAM: 6.75 mean: 3.926 median: 2.52 low: 0.021 |
|
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | -1.351 | |
| Cost Of Debt | 7.751 % | |
| Interest Coverage Ratio | -9.908 | |
| Interest Coverage Ratio QoQ | 0.725 % | |
| Interest Coverage Ratio YoY | 34.03 % | |
| Interest Coverage Ratio IPRWA | high: 940.414 mean: 44.611 median: 2.742 BEAM: -9.908 low: -1580.294 |
|
| Operating Cash Flow Ratio | -0.539 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | -5.165 % | |
| Revenue Growth | 13.333 % | |
| Revenue Growth QoQ | -117.741 % | |
| Revenue Growth YoY | -77.35 % | |
| Revenue Growth IPRWA | high: 269.352 % mean: 20.423 % BEAM: 13.333 % median: 12.272 % low: -259.856 % |
|
| Earnings Growth | -19.355 % | |
| Earnings Growth QoQ | -240.651 % | |
| Earnings Growth YoY | 134.209 % | |
| Earnings Growth IPRWA | high: 155.0 % median: 11.33 % mean: 2.423 % BEAM: -19.355 % low: -181.25 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | -1419.218 % | |
| EBIT Margin QoQ | -11.125 % | |
| EBIT Margin YoY | 59.274 % | |
| EBIT Margin IPRWA | high: 338.783 % median: 23.755 % mean: -72.803 % BEAM: -1419.218 % low: -5123.44 % |
|
| Return On Sales (ROS) | -1419.218 % | |
| Return On Sales QoQ | -11.125 % | |
| Return On Sales YoY | 59.274 % | |
| Return On Sales IPRWA | high: 89.247 % median: 28.85 % mean: -76.625 % BEAM: -1419.218 % low: -5698.0 % |
|
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -79.59 M | |
| Free Cash Flow Yield | -4.315 % | |
| Free Cash Flow Yield QoQ | -11.957 % | |
| Free Cash Flow Yield YoY | 11.355 % | |
| Free Cash Flow Yield IPRWA | high: 36.371 % median: 0.516 % mean: -0.332 % BEAM: -4.315 % low: -74.318 % |
|
| Free Cash Growth | -25.585 % | |
| Free Cash Growth QoQ | -173.505 % | |
| Free Cash Growth YoY | 51.867 % | |
| Free Cash Growth IPRWA | high: 157.51 % median: 13.562 % mean: 3.883 % BEAM: -25.585 % low: -183.577 % |
|
| Free Cash To Net Income | 0.778 | |
| Cash Flow Margin | -1109.095 % | |
| Cash Flow To Earnings | 0.918 | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | -7.158 % | |
| Return On Assets QoQ | -15.798 % | |
| Return On Assets YoY | 3.022 % | |
| Return On Assets IPRWA | high: 36.544 % median: 1.616 % mean: -1.386 % BEAM: -7.158 % low: -68.545 % |
|
| Return On Capital Employed (ROCE) | -9.873 % | |
| Return On Equity (ROE) | -0.098 | |
| Return On Equity QoQ | 0.442 % | |
| Return On Equity YoY | -8.339 % | |
| Return On Equity IPRWA | high: 1.117 median: 0.04 mean: 0.008 BEAM: -0.098 low: -1.572 |
|
| DuPont ROE | -9.421 % | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |